Héritas

What Héritas does

Héritas S.A. is an Argentine precision medicine company founded in 2015 and headquartered in Rosario, Santa Fe, operating an ISO 9001:2015-certified genomic diagnostic laboratory (most recently expanded inside CIBIC Laboratorios' CEPIDE facility, inaugurated December 2023). The company delivers clinical genomics services across four pillars: reproductive genomics led by its proprietary NIPT VISIÓN assay (13,200+ tests as of November 2025 with 99.7% sensitivity / 99.96% specificity for Trisomy 21); hereditary and somatic oncology through the CLEAR 112-gene panel, OncoSens, and a myeloid panel powered by SOPHiA GENETICS; rare and inherited disease diagnostics via FOCUS clinical exome, FOCUS Mito mitochondrial exome, CARDIO (174 genes across 17 hereditary cardiovascular conditions), and CHROMO microarray; plus a wellness/prevention line built on the Rewell platform and MicroXplora microbiome analysis with proprietary Argentine reference data and PRS-based risk modeling.

The technology stack combines Illumina NextSeq 2000 / NextSeq 500 / MiSeq and ThermoFisher Ion GeneStudio S5 sequencing platforms with a proprietary AI/ML layer including a four-score NIPT interpretation algorithm, the VUS Monitor for automated variant reclassification, an in-house HPO term conversion model, and the Rewell recommendation engine, augmented by best-in-class third-party tools (FDNA Face2Gene for phenotypic deep learning, Genomenon Mastermind for NLP-driven variant classification). Co-founder Martín Vázquez, a CONICET Independent Researcher and Illumina Latin America KOL since 2015, anchors the scientific credibility.

Commercial operations are routed exclusively through CIBIC Laboratorios as commercial distributor, which manages quotations, sample logistics, and patient service across Argentina, with Paraguay reached via a Meyer Lab distribution partnership launched in 2022. End customers span individual patients (per-test fees for NIPT, exome, oncology panels), wellness subscribers (Rewell), professional education students (Héritas Academy courses, e.g., ARS 7,000–8,400 for the Molecular Biology program), and Argentine hospitals engaged in joint research (Hospital Alemán, Británico, Italiano, Austral, Hospital Privado de Córdoba, CEMA, plus IBR-CONICET). Revenue is generated through one-time per-test diagnostic fees, professional services for genetic counseling and courses, and a growing recurring subscription component from the Rewell wellness line, with pricing handled directly via CIBIC quotations rather than public disclosure.

Name

Héritas

Legal name

Héritas S.A.

Website

https://heritas.com.ar

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Short description

Héritas is an Argentine precision medicine company founded in 2015 in Rosario, offering genomic diagnostic services including NIPT, hereditary cancer and cardiovascular panels, clinical exome, chromosomal microarray, and microbiome analysis. It serves patients, hospitals, and researchers across Argentina and Paraguay via an exclusive CIBIC distributor.

Ownership category

akta.pro rank

Headquarters

HQ city

Buenos Aires

HQ country

Argentina

HQ region

Latin America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Revenue model

1. Genomic Diagnostic Services: Laboratory diagnostic services for clinical genomics including NIPT, exome sequencing, hereditary cancer panels, chromosomal microarray, and hereditary cardiomyopathies. Revenue generated through per-test fees billed to patients via CIBIC distributor.
2. Genetic Counseling: Pre and post-test genetic counseling consultations. Free for patients undergoing tests at Héritas; charged for independent consultations.
3. Rewell Wellness Platform: Wellness and prevention services including microbiome analysis, genetic predisposition testing, and nutritional coaching for chronic disease prevention and healthy longevity
4. Educational Programs: Professional education courses for healthcare workers including Molecular Biology applied to Medical Diagnostics course

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

No source content with verifiable source IDs was provided in the input. Core offering cannot be populated without supporting evidence.

Product overview

Héritas is a precision medicine company offering a comprehensive genomic diagnostic platform with multiple specialized products and services. The core offerings include: (1) Clinical Genomics - CARDIO for hereditary cardiovascular diseases, FOCUS/FOCUS Mito for complete/mitochondrial exome analysis; (2) Oncology - CLEAR hereditary cancer panel (112 genes), OncoSens, and Panel Mieloide using SOPHiA GENETICS; (3) Reproductive Genomics - Héritas VISIÓN NIPT with proprietary four-score algorithm; (4) Wellness - Rewell microbiome and genetic prevention platform with MicroXplora; (5) Genetic Counseling - GEN24 teleconsultation platform. Key technology differentiators include VUS Monitor for variant monitoring, AI-powered HPO term conversion, and PRS for polygenic risk assessment. The company operates its own ISO 9001-certified laboratory in Rosario, Argentina.

Differentiator

Problem solved

Functional benefit

Brands

• Rewell: A wellness and prevention platform focused on gut microbiome analysis, genetic predisposition to health conditions, and personalized lifestyle plans for healthy longevity.
• Gen24
• FOCUS
• CARDIO
• CLEAR
• CHROMO
• MicroXplora

Quantifiable outcome

• 99.7% sensitivity and 99.96% specificity for Trisomy 21 detection
• +2 more outcomes

Named customers6 records

Segments6 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability13 records

Feature5 records

Partnerships

16 partnerships are on record, tiered core and minor.

• Meyer Lab ParaguaycoreChannel Partner/ Reseller/ Distributor · 1 May 2022Distribution partnership for Héritas services launch in Paraguay. Launch event held in Asunción with approximately 100 medical referents attending.
• Hospital Alemán de Buenos AirescoreStrategic or Co-development PartnerResearch partnership for validation of NGS technology for detection of somatic mutations in circulating tumor DNA (ctDNA). Study status: Finalized.
• Centro de Mastología Rosario (CEMA)coreStrategic or Co-development PartnerOngoing collaboration for detection of actionable mutations in tissue and plasma from breast cancer patients using massive sequencing.
• Hospital Británico de Buenos AirescoreStrategic or Co-development PartnerProspective validation study for monitoring and prognosis of stage IV breast, colon, and lung tumor treatment via circulating tumor DNA mutation mapping determined by NGS. Status: Pre-approval.
• Hospital Italiano de Buenos AirescoreStrategic or Co-development PartnerResearch collaboration on mutational profiling assessment in patients with myelodysplastic syndromes and acute myeloid leukemias.
• Instituto de Biología Molecular y Celular de Rosario (IBR)coreStrategic or Co-development PartnerCollaboration for identification of new markers associated with hereditary cancer.
• Hospital Austral Buenos AirescoreStrategic or Co-development PartnerPilot case-control study on microbiome in patients with cirrhosis with and without hepatocellular carcinoma. Status: Completed. Ongoing multicenter nested case-control study on longitudinal prospective cohort.
• Instituto de Medicina Experimental-CONICET-Academia Nacional de MedicinacoreStrategic or Co-development PartnerMulticenter study collaboration on microbiome in patients with cirrhosis who develop hepatocellular carcinoma.
• NeuroBioMind (Dr. Tomás Maresca)minorStrategic or Co-development PartnerPilot case-control study on microbiome of depressive patients treated with antidepressants with and without probiotics.
• Laboratorio Inmunogénesis/Laboratorio ABMminorStrategic or Co-development PartnerMICROGÉNESIS study on association between gastrointestinal autoimmunity, dysbiosis and infertility for identification of diagnostic parameters and potential treatment targets.
• IlluminacoreTechnology or IntegrationPrimary sequencing technology partner providing NGS platforms (NextSeq 2000, NextSeq 500, MiSeq, iScan) for genomic data production. Co-founder Martín Vázquez serves as Key Opinion Leader for Illumina Latin America since 2015.
• ThermoFisher ScientificcoreTechnology or IntegrationTechnology partner providing Ion GeneStudio S5 System sequencer, expanding Héritas' NGS capabilities.
• SOPHiA GENETICScoreTechnology or IntegrationTechnology partner providing Myeloid Plus Solution for molecular diagnosis of myelodysplastic syndromes, myeloproliferative neoplasms, and acute leukemias via NGS.
• CIBIC LaboratorioscoreChannel Partner/ Reseller/ DistributorExclusive commercial distributor for all Héritas products. Coordinates patient quotations, sample logistics, and customer service.
• Genotipia e IlluminaminorGTM or Marketing PartnerJoint webinar series on 'Massive sequencing (NGS) in clinical practice' with over 300 participants from Central America, Latin America, and Spain.
• Círculo Médico de RosariominorGTM or Marketing PartnerEducational partnership for Molecular Biology course with 6 years of history, coordinated by Director Científico Martín Vázquez.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• SOPHiA GENETICS: Genomic and multimodal AI platform for hereditary and somatic cancer, already a Héritas technology partner for the Myeloid Plus Solution — overlapping NGS-driven oncology analytics and AI variant interpretation.
• 23andMe: Consumer genetics and prevention platform; adjacent comparable to Héritas's Rewell wellness/microbiome consumer offering, especially around subscription-based prevention and longevity positioning.
• Genotipia: Spain/LATAM-focused clinical genetics education and service platform — adjacent comparable given Héritas's Héritas Academy offering and joint Genotipia-Illumina webinar series.

Direct peers

• Natera: US-listed molecular diagnostics company with leading NIPT (Panorama) and oncology liquid biopsy franchises — competes in the same NIPT and oncology genomics categories as Héritas VISIÓN and OncoSens.
• Igenomix: Global reproductive genomics laboratory offering NIPT, PGT, and carrier screening with LATAM presence — directly comparable to Héritas's NIPT Vision, FOCUS exome, and reproductive genomics portfolio.

Regional players

• Mendelics: Brazilian clinical genomics laboratory offering NIPT, exome, and hereditary cancer panels — most direct regional comparable on test menu and LATAM market dynamics.
• Dasa: Brazil's largest diagnostic medicine network with growing genomics capabilities via its genomic subsidiary; serves an analogous integrated hospital-lab model in LATAM.

Broad incumbents

• BGI Genomics: World's largest NIPT provider by volume and a global NGS clinical services player; a key competitive benchmark for Héritas's NIPT and reproductive genomics lines at scale.
• Invitae (Labcorp Genetics): Large US clinical genetic testing platform (now part of Labcorp) covering hereditary cancer, reproductive, and rare disease — broad incumbent comparable to Héritas's full-menu clinical genomics offering.
• Myriad Genetics: Established US hereditary cancer and pharmacogenomics player; directly comparable to Héritas CLEAR hereditary cancer panel (112 genes) and broader oncology testing franchise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/HeritasArg
• YouTubeyoutube.com/channel/UCYp3QeCST1ros-xP_pFcMXg
• LinkedInlinkedin.com/company/héritas
• Instagraminstagram.com/heritasarg
• Facebookfacebook.com/heritasArg

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Héritas